2018
DOI: 10.1177/0897190018767769
|View full text |Cite
|
Sign up to set email alerts
|

Systemic Thrombolytic Therapy for Massive and Submassive Pulmonary Embolism

Abstract: Patients with massive PE should receive thrombolytics when no major contraindications to therapy exist. Patients with submassive PE at highest risk for progression to hemodynamic instability should receive anticoagulation and be monitored for clinical deterioration. If an imminent risk of hemodynamic instability or cardiac arrest occurs, thrombolytics should be administered if no contraindications exist. Net mortality benefit and risk of bleeding must be considered when deciding to administer thrombolytic ther… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
14
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 17 publications
(15 citation statements)
references
References 49 publications
(120 reference statements)
0
14
0
Order By: Relevance
“…Massive PE is a rare but life‐threatening form of VTE that poses a significant challenge in postoperative patients 1,4,6 . In patients with contraindications to systemic tPA, endovascular interventions are now increasingly favored over traditional surgical thrombectomy due to decreased rates of morbidity and mortality 7,8,10 .…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Massive PE is a rare but life‐threatening form of VTE that poses a significant challenge in postoperative patients 1,4,6 . In patients with contraindications to systemic tPA, endovascular interventions are now increasingly favored over traditional surgical thrombectomy due to decreased rates of morbidity and mortality 7,8,10 .…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, patients presenting with massive PE have a mortality rate of up to 30%–50% 2,4,5 . Postoperative massive PE poses a significant challenge as recent surgery is often an absolute contraindication to systemic tissue plasminogen activator (tPA) due to bleeding risks 6 . In such cases, surgical thrombectomy is often possible but carries a high morbidity and mortality rate 7,8 .…”
Section: Introductionmentioning
confidence: 99%
“…The use of thrombolytic therapy is another treatment approach for the management of patients with acute PE. While thrombolytic therapy is advised in patients with massive PE to mitigate hemodynamic collapse, its benefit in patients with submassive PE is less well-defined given the increased risk of major and minor bleeding [ 8 ]. A meta-analysis of 16 studies was performed to compare the use of thrombolytic therapy and anticoagulation in patients with PE.…”
Section: Discussionmentioning
confidence: 99%
“…PE may be classified as high risk, intermediate, or low risk. When patients with acute pulmonary embolism present with hypotension defined as a systolic blood pressure <90mmHg or drop of >40mmHg, not explained by another cause, this is referred to as high risk PE in the European Guidelines [12, 13]. Thrombolytic therapy should be administered unless contraindicated, as the 30-day mortality risk is greater than 15% in this population.…”
Section: Discussionmentioning
confidence: 99%
“…American College of Chest Physicians guidelines suggest that recent surgery, excluding recent brain or spinal surgery or trauma, is a relative contraindication and that the bleeding risk reduces significantly 2weeks after surgery. [12].…”
Section: Discussionmentioning
confidence: 99%